Very high TAFI antigen levels are associated with a lower risk of hard coronary events: The PRIME Study

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 10, 2003, Pages 2243-2244

  Juhan Vague, I ^a   Morange, P E ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CARBOXYPEPTIDASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

BIOSYNTHESIS; CASE CONTROL STUDY; CORONARY ARTERY ATHEROSCLEROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEART INFARCTION; HUMAN; LETTER; MALE; MORTALITY; PATHOLOGY; RISK;

ANTIGENS; CARBOXYPEPTIDASE U; CARBOXYPEPTIDASES; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HUMANS; MALE; MYOCARDIAL INFARCTION; RISK;

EID: 1542297149     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00398.x     Document Type: Letter

References (8)

1. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrino-lytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-8.
2. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
3. Schroeder V, Chatterjee T, Mehta H, Windecker S, PhamT, Devantay N, Meier B, Kohler HP. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiogra-phy. Thromb Haemost 2002; 88: 1020-5.
4. Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study. Thromb Haemost 2003; 89:554-60.
5. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegard A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group. Plasma thrombin-activatable ibrinolysis inhibitor (TAFI) antigen concentration and TAFI genotype in relation to myocardial infarction in the north and south of Europe. Arterisocler Thromb Vasc Biol 2002; 22: 867-73.
6. Yarnell JWG. The PRIME study. classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Q J Med 1998; 91: 667-76.
7. Ducimetiere P, Ruidavets JB, Montaye M, Haas B, Yarnell JWG; PRIME Study Group. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol 2001; 30: 1057-62.
8. Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83:902-5.